IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company developing protein kinase inhibitors to modify the course of Parkinson's disease and related neurodegenerative disorders. The company's lead product candidate, IkT-148009, is designed to inhibit c-Abl, a protein kinase that has been implicated in the progression of Parkinson's disease by promoting the accumulation of toxic protein aggregates. Inhibikase is conducting clinical trials to evaluate IkT-148009's potential to slow or stop disease progression rather than just treating symptoms. The company represents a novel approach to addressing neurodegenerative diseases by targeting underlying disease mechanisms at the molecular level.